|
|
|
| home > ebr > winter 2019 > challenges for small businesses in the global pharma market |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review
|
|
The pharmaceutical industry was considered a relatively ‘safe’ environment in which to be employed in the early 1990s. It was seen by many to be a recession-proof business where intellectual property (IP) and patents in particular were critical to profitability.
The business was global and powered by huge researchbased companies: Big Pharma, who took drugs all the way from preclinical research, through clinical development, to commercialisation. Companies like Glaxo, Merck, Pfizer, Eli Lilly, Bayer, and, in Sweden, the likes of Astra and Pharmacia, were multinational R&D-based powerhouses that dominated the life sciences landscape. In 1995, Astra had the biggest selling drug in the world: the proton pump inhibitor Losec® (omeprazole) and employed thousands of people in R&D. To its employees (which included the author at the time), the company seemed invincible.
The Changing Landscape
Drugs commanded high prices in the developed world, which represented almost the entire market in terms of value, with the US market being by far the most lucrative. Although the Hatch- Waxman Act – a US federal law designed to encourage generic drug manufacture and sale with a view to lowering prices – had been around for just a few years, generics companies were still somewhat smaller and often local organisations that tended not to enter the market until at least the basic patent covering a drug expired.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Switzerland overtakes Germany as Europe’s biggest drug delivery innovator, with the UK and France close behind
Paris, 19th August 2019: As predicted by the ‘European drug delivery and packaging’ report earlier this year, new data shows innovation in drug delivery is accelerating across Europe – with provisional findings from the Pharmapack Innovation Index (2020) showing that Switzerland has over taken Germany as Europe’s most innovative drug delivery market.
More info >> |
|
 |
White Papers |
 |
|
The Role of the CRO in Effective Risk-Based Monitoring
Medpace
The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >> |
|
 |
Industry Events |
 |
ELRIG Drug Discovery 2019 – Looking Back to the Future
5-6 November 2019, ACC, Liverpool
Now in its 13th year, ELRIG’s flagship conference Drug Discovery 2019 will take place at
ACC in Liverpool.
This year’s focus, ‘A Look Back to the Future’ is planned to include plenary introductions
assessing how we got to where we are now and setting the challenges for discovering the
drugs of the future. These will be followed by cutting edge talks and examples of new
directions in drug discovery.
Our scientific programme will feature over 40 world-class speakers with 6 main session
tracks. In partnership with key academic and charitable groups, we will also run joint
disease and biology-oriented tracks focusing on the basic sciences that underpin
successful drug discovery.
More info >> |
|
|
